Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense Incurred During the Second Quarter of 2022 (Unaudited) (In millions, except per share data) Quarter Ended
Thursday, June 30, 2022 BiopharmaWatch Research 1 min read
Key Takeaway: Guidance Including the Impact of Acquired IPR D and Milestones Expense Incurred During the Second Quarter of 2022
(Unaudited) (In millions, except per share data)
Quarter Ended June 30, 2022 Full-Year Ended December 31, 2022 Acquired IPR D and Milestones Expense Adjusted Di
Price reaction · baseline $154.14 (2022-06-29 close) · hit after-hours · clean, no other ABBV news in the window
day 0 close · peak
-0.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+33%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
paricalcitol
Phase 3 · Secondary Hyperparathyroidism
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense Incurred During the Second Quarter of 2022
(Unaudited) (In millions, except per share data)
Quarter Ended June 30, 2022
Full-Year Ended December 31, 2022
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q2 2022 acquired IPR D and milestones expense
$
-
$
3.38
$
3.42
$
145
$
13.92
$
14.12
Q2 2022 acquired IPR D and milestones expense
269
(0.14)
(0.14)
269
(0.14)
(0.14)
Guidance including Q2 2022 acquired IPR D and milestones expense a
$
269
$
3.24
$
3.28
$
414
$
13.78
$
13.98
a The Company's 2022 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the second quarter of 2022, as both cannot be reliably forecasted.